3.17
+0.06(+1.93%)
Currency In USD
| Previous Close | 3.11 |
| Open | 3 |
| Day High | 3.19 |
| Day Low | 2.91 |
| 52-Week High | 13.28 |
| 52-Week Low | 1.17 |
| Volume | 2.07M |
| Average Volume | 9.75M |
| Market Cap | 19.2M |
| PE | -0.27 |
| EPS | -11.9 |
| Moving Average 50 Days | 3.31 |
| Moving Average 200 Days | 3.29 |
| Change | 0.06 |
If you invested $1000 in BioXcel Therapeutics, Inc. (BTAI) since IPO date, it would be worth $17.96 as of September 15, 2025 at a share price of $3.17. Whereas If you bought $1000 worth of BioXcel Therapeutics, Inc. (BTAI) shares 5 years ago, it would be worth $4.1 as of September 15, 2025 at a share price of $3.17.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025
GlobeNewswire Inc.
Aug 26, 2025 8:00 PM GMT
Company to host conference call at 8 a.m. ET, August 27, 2025NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medi
BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
GlobeNewswire Inc.
Aug 19, 2025 11:00 AM GMT
Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artifici